Latest information on COVID-19


Welcome to the Division of Immunology and Rheumatology. We strive to provide outstanding care for patients with immune-mediated and rheumatic disease, including rheumatoid arthritis, systemic lupus erythematosus,ankylosing spondylitis, psoriatic arthritis, systemic sclerosis, poly- and dermatomyositis, vasculitis, gout and osteoarthritis. We bring the benefit of pioneering research to our patients and educate the next generation of specialists in the diagnosis, treatment and exploration of autoimmune disease.


Mission Statement

To understand and treat immune-mediated and rheumatic diseases pursuing the highest standards of excellence in research, patient care, and education.

Overarching Objectives

  • To advance paradigm-shifting biomedical research into the causes and treatment of human disease
  • To educate physician-investigators of the highest integrity and ever-expanding expertise
  • To provide comprehensive and transformative care for the prevention, diagnosis and treatment of rheumatic and immune mediated diseases
  • To promote diversity and inclusion



The commitment of Stanford has enabled the recruitment of new faculty members to our Division in the past five years, construction of new facilities (the Center for Clinical Sciences Research, (CCSR), and administrative reorganization to provide a critical mass and optimal environment for collaborative research and training within the field of adult rheumatology.

The goal of our Division is to leverage these institutional resources to perform leading research, provide superb clinical care, and prepare highly qualified candidates for careers as academic physician-scientists in the field of rheumatology.

Featured News

November 2019

Division faculty member Dr. P.J. Utz is the Medical Honoree of the Arthritis Foundation's Jingle Bell Run 2019.

September 2019

William (Bill) Robinson, MD, PhD was appointed as the Chief for the Division of Immunology and Rheumatology in the Department of Medicine as of September 1, 2019.

July 2019

Novel rheumatoid arthritis drug succeeds in clinical trial. The results from Dr. Mark Genovese's trial were published on July 23, 2019 in JAMA.

How to Get Involved

Upcoming Events